Precigen (PGEN) Income from Continuing Operations (2012 - 2026)
Precigen (PGEN) posted quarterly Income from Continuing Operations of 7929000.0 for Q1 2026, up 85.36% year-over-year from 4277664.57 in Q1 2025, and up 66.26% quarter-over-quarter from 23503000.0 in Q4 2025.
Powered by 
Analysis
Precigen (PGEN) Income from Continuing Operations (2012 - 2026) Analysis & Trends
Precigen (PGEN) has reported Income from Continuing Operations for 15 consecutive years, with 7929000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 85.36% year-over-year to 7929000.0; the TTM figure through Mar 2026 stood at 204418000.0 (down 30.49% YoY), while the FY2025 annual figure was 250642000.0, down 98.55% from the prior year.
- Income from Continuing Operations rose to 7929000.0 in Q1 2026 per PGEN's latest filing, from 23503000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 7644000.0 in Q3 2022 and bottomed at 146344000.0 in Q3 2025.
- Historically, Income from Continuing Operations has averaged 32969823.53 across 5 years, with a median of 23738000.0 in 2024.
- Annual changes were most pronounced in 2025 — Income from Continuing Operations plunged 510.33% — and 2026, when it surged 85.36%.
- Precigen's Income from Continuing Operations stood at 22176000.0 in 2022, then sank by 49.06% to 33056000.0 in 2023, then soared by 40.32% to 19727000.0 in 2024, then dropped by 19.14% to 23503000.0 in 2025, then jumped by 66.26% to 7929000.0 in 2026.
- Business Quant data shows PGEN's Income from Continuing Operations at 7929000.0 in Q1 2026, 23503000.0 in Q4 2025, and 146344000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Precigen | 2.53 Bn | 2.53 Bn | 52.17 Mn | 20.07 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 20.07 Mn |
| Mar 31, 2026 | -7.93 Mn |
| Dec 31, 2025 | -23.50 Mn |
| Sep 30, 2025 | -146.34 Mn |
| Jun 30, 2025 | -26.64 Mn |
| Mar 31, 2025 | -54.15 Mn |
| Dec 31, 2024 | -19.73 Mn |
| Sep 30, 2024 | -23.98 Mn |
| Jun 30, 2024 | -58.79 Mn |
| Mar 31, 2024 | -23.74 Mn |
| Dec 31, 2023 | -33.06 Mn |
| Sep 30, 2023 | -19.80 Mn |
| Jun 30, 2023 | -20.32 Mn |
| Mar 31, 2023 | -22.73 Mn |
| Dec 31, 2022 | -22.18 Mn |
| Sep 30, 2022 | -7.64 Mn |
| Jun 30, 2022 | -26.06 Mn |
| Mar 31, 2022 | -23.90 Mn |
| Dec 31, 2021 | -26.70 Mn |
| Sep 30, 2021 | -26.32 Mn |